|
Market Closed -
Japan Exchange
02:30:00 2026-09-11 EDT
|
5-day change | 1st Jan Change | ||
| 6,501.00 JPY | -1.29% |
|
-4.75% | -18.15% |
Business description: COSMOS Pharmaceutical Corporation
Number of employees: 5,984
Sales by Activity: COSMOS Pharmaceutical Corporation
| Fiscal Period: May | 2022 (JPY) | 2023 (JPY) | 2024 (JPY) | 2025 (JPY) | 2026 (JPY) |
|---|---|---|---|---|---|
Retail Business of Pharmaceuticals and Cosmetics | 755B | 828B | 965B | 1,011B | 1,100B |
Geographical breakdown of sales: COSMOS Pharmaceutical Corporation
| Fiscal Period: May | 2022 (JPY) | 2023 (JPY) | 2024 (JPY) | 2025 (JPY) | 2026 (JPY) |
|---|---|---|---|---|---|
Japan | 755B | 828B | 965B | 1,011B | 1,100B |
Executive Committee: COSMOS Pharmaceutical Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
Hideaki Yokoyama
PSD | President | 46 | 2018-05-31 |
Fumiyasu Uno
PRN | Corporate Officer/Principal | 49 | 2007-05-31 |
Motoi Takemori
DFI | Director of Finance/CFO | 61 | 2022-01-15 |
Composition of the Board of Directors: COSMOS Pharmaceutical Corporation
| Director | Title | Age | Since |
|---|---|---|---|
Motoi Takemori
BRD | Director/Board Member | 61 | 2026-08-27 |
Hideaki Yokoyama
BRD | Director/Board Member | 46 | 2016-07-31 |
| Director/Board Member | 66 | 2019-08-22 | |
Chiyoko Harada
BRD | Director/Board Member | 52 | 2021-08-23 |
Yuki Watanabe
BRD | Director/Board Member | 55 | 2022-07-31 |
Fumiyasu Uno
BRD | Director/Board Member | 49 | 2025-07-31 |
Holdings: COSMOS Pharmaceutical Corporation
| Name | Stocks | % | Valuation |
|---|---|---|---|
| 744,300 | 0.93% | 30 M $ | |
| 500 | 0% | 7 229 $ | |
| 100 | 0% | 2 337 $ | |
| 100 | 0% | 2 333 $ | |
| 100 | 0% | 2 126 $ | |
| 200 | 0% | 1 654 $ |
Company details: COSMOS Pharmaceutical Corporation
COSMOS Pharmaceutical Corp.
Daiichi Fukuoka Building S-Wing, 4/F
812-0013, Fukuoka
+
http://www.cosmospc.co.jp
Retail - Drugs with Grocery
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.29% | -4.75% | -28.19% | -22.75% | 3.35B | |
| -1.47% | -3.17% | -9.51% | +4.96% | 6.63B | |
| -2.09% | -4.96% | -34.95% | +18.67% | 2.98B | |
| -0.16% | -1.64% | -19.84% | -15.73% | 2.79B | |
| -0.65% | -5.17% | +0.63% | +31.41% | 2.47B | |
| -5.24% | -7.35% | -28.03% | -37.29% | 1.41B | |
| -0.15% | -3.36% | -2.07% | -9.81% | 1.39B | |
| 0.00% | -0.80% | +28.76% | +60.84% | 542M | |
| -2.37% | -3.01% | -25.04% | -7.71% | 343M | |
| -1.49% | -1.93% | -46.11% | -72.72% | 314M | |
| Average | -1.49% | -3.77% | -16.43% | -5.01% | 2.22B | |
| Weighted average by Cap. | -1.41% | -3.98% | -16.44% | -0.58% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 3349 Stock
- Company COSMOS Pharmaceutical Corporation
Select your edition
All financial news and data tailored to specific country editions
